{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:38:49Z","timestamp":1792172329675,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fragile-X syndrome (FXS) patients display intellectual disability and autism spectrum disorder due to silencing of the X-linked, fragile-X mental retardation-1 (<jats:italic>FMR1<\/jats:italic>) gene. Dysregulation of cAMP metabolism is a consistent finding in patients and in the mouse and fly FXS models. We therefore explored if BPN14770, a prototypic phosphodiesterase-4D negative allosteric modulator (PDE4D-NAM) in early human clinical trials, might provide therapeutic benefit in the mouse FXS model. Daily treatment of adult male <jats:italic>fmr1<\/jats:italic> C57Bl6 knock-out mice with BPN14770 for 14 days reduced hyperarousal, improved social interaction, and improved natural behaviors such as nesting and marble burying as well as dendritic spine morphology. There was no decrement in behavioral scores in control C57Bl6 treated with BPN14770. The behavioral benefit of BPN14770 persisted two weeks after washout of the drug. Thus, BPN14770 may be useful for the treatment of fragile-X syndrome and other disorders with decreased cAMP signaling.<\/jats:p>","DOI":"10.1038\/s41598-017-15028-x","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T10:36:54Z","timestamp":1509532614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D)"],"prefix":"10.1038","volume":"7","author":[{"given":"Mark E.","family":"Gurney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cogram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Rex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tranfaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"15028_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","volume":"65","author":"AJ Verkerk","year":"1991","unstructured":"Verkerk, A. J. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell \n                           65, 905\u2013914 (1991).","journal-title":"Cell"},{"key":"15028_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1542\/peds.2008-0317","volume":"123","author":"RJ Hagerman","year":"2009","unstructured":"Hagerman, R. J. et al. Advances in the treatment of fragile X syndrome. Pediatrics \n                           123, 378\u2013390 (2009).","journal-title":"Pediatrics"},{"key":"15028_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5582\/irdr.2016.01048","volume":"5","author":"R Lozano","year":"2016","unstructured":"Lozano, R., Azarang, A., Wilaisakditipakorn, T. & Hagerman, R. J. Fragile X syndrome: A review of clinical management. Intractable Rare Dis Res \n                           5, 145\u2013157 (2016).","journal-title":"Intractable Rare Dis Res"},{"key":"15028_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/hmg\/10.4.329","volume":"10","author":"B Laggerbauer","year":"2001","unstructured":"Laggerbauer, B., Ostareck, D., Keidel, E. M., Ostareck-Lederer, A. & Fischer, U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet \n                           10, 329\u2013338 (2001).","journal-title":"Hum Mol Genet"},{"key":"15028_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","volume":"146","author":"JC Darnell","year":"2011","unstructured":"Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell \n                           146, 247\u2013261 (2011).","journal-title":"Cell"},{"key":"15028_CR6","first-page":"23","volume":"78","author":"Fmr1","year":"1994","unstructured":"Fmr1. knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell \n                           78, 23\u201333 (1994).","journal-title":"Cell"},{"key":"15028_CR7","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0896-6273(02)00731-6","volume":"34","author":"J Morales","year":"2002","unstructured":"Morales, J. et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron \n                           34, 961\u2013972 (2002).","journal-title":"Neuron"},{"key":"15028_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1523\/JNEUROSCI.1356-12.2015","volume":"35","author":"CH Choi","year":"2015","unstructured":"Choi, C. H. et al. PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome. J Neurosci \n                           35, 396\u2013408 (2015).","journal-title":"J Neurosci"},{"key":"15028_CR9","doi-asserted-by":"publisher","first-page":"13111","DOI":"10.1523\/JNEUROSCI.1347-12.2012","volume":"32","author":"AK Kanellopoulos","year":"2012","unstructured":"Kanellopoulos, A. K., Semelidou, O., Kotini, A. G., Anezaki, M. & Skoulakis, E. M. Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila. J Neurosci \n                           32, 13111\u201313124 (2012).","journal-title":"J Neurosci"},{"key":"15028_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/ajmg.1320450120","volume":"45","author":"E Berry-Kravis","year":"1993","unstructured":"Berry-Kravis, E. & Sklena, P. Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. American Journal of Medical Genetics \n                           45, 81\u201387 (1993).","journal-title":"American Journal of Medical Genetics"},{"key":"15028_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1203\/00006450-199511000-00002","volume":"38","author":"E Berry-Kravis","year":"1995","unstructured":"Berry-Kravis, E., Hicar, M. & Ciurlionis, R. Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. Pediatric Research \n                           38, 638\u2013643 (1995).","journal-title":"Pediatric Research"},{"key":"15028_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0092-8674(01)00589-X","volume":"107","author":"YQ Zhang","year":"2001","unstructured":"Zhang, Y. Q. et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell \n                           107, 591\u2013603 (2001).","journal-title":"Cell"},{"key":"15028_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0896-6273(02)00724-9","volume":"34","author":"TC Dockendorff","year":"2002","unstructured":"Dockendorff, T. C. et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron \n                           34, 973\u2013984 (2002).","journal-title":"Neuron"},{"key":"15028_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.neuron.2005.01.038","volume":"45","author":"SM McBride","year":"2005","unstructured":"McBride, S. M. et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron \n                           45, 753\u2013764 (2005).","journal-title":"Neuron"},{"key":"15028_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/nn.2175","volume":"11","author":"FV Bolduc","year":"2008","unstructured":"Bolduc, F. V., Bell, K., Cox, H., Broadie, K. S. & Tully, T. Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nature Neuroscience \n                           11, 1143\u20131145 (2008).","journal-title":"Nature Neuroscience"},{"key":"15028_CR16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay, M. D., Schafer, P. & Zhang, K. Y. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today \n                           10, 1503\u20131519 (2005).","journal-title":"Drug Discov Today"},{"key":"15028_CR17","unstructured":"Gurney, M. E. et al. Heteroaryl Inhibitors of PDE4. United States Patent US 9,221,843 B2 (2015)."},{"issue":"Pt 1","key":"15028_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1042\/bj3330139","volume":"333","author":"R Hoffmann","year":"1998","unstructured":"Hoffmann, R., Wilkinson, I. R., McCallum, J. F., Engels, P. & Houslay, M. D. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J \n                           333(Pt 1), 139\u2013149 (1998).","journal-title":"Biochem J"},{"key":"15028_CR19","doi-asserted-by":"publisher","first-page":"16526","DOI":"10.1074\/jbc.271.28.16526","volume":"271","author":"C Sette","year":"1996","unstructured":"Sette, C. & Conti, M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem \n                           271, 16526\u201316534 (1996).","journal-title":"J Biol Chem"},{"key":"15028_CR20","doi-asserted-by":"publisher","first-page":"E2328","DOI":"10.1210\/jc.2012-2326","volume":"97","author":"A Linglart","year":"2012","unstructured":"Linglart, A. et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. The Journal of Clinical Endocrinology and Metabolism \n                           97, E2328\u20132338 (2012).","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"15028_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/ajmg.1320300416","volume":"30","author":"MG Butler","year":"1988","unstructured":"Butler, M. G., Rames, L. J. & Wadlington, W. B. Acrodysostosis: report of a 13-year-old boy with review of literature and metacarpophalangeal pattern profile analysis. American Journal of Medical Genetics \n                           30, 971\u2013980 (1988).","journal-title":"American Journal of Medical Genetics"},{"key":"15028_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ajhg.2012.03.004","volume":"90","author":"H Lee","year":"2012","unstructured":"Lee, H. et al. Exome sequencing identifies PDE4D mutations in acrodysostosis. American Journal of Human Genetics \n                           90, 746\u2013751 (2012).","journal-title":"American Journal of Human Genetics"},{"key":"15028_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ajhg.2012.03.003","volume":"90","author":"C Michot","year":"2012","unstructured":"Michot, C. et al. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. American Journal of Human Genetics \n                           90, 740\u2013745 (2012).","journal-title":"American Journal of Human Genetics"},{"key":"15028_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/humu.22222","volume":"34","author":"DC Lynch","year":"2013","unstructured":"Lynch, D. C. et al. Identification of novel mutations confirms Pde4d as a major gene causing acrodysostosis. Human Mutation \n                           34, 97\u2013102 (2013).","journal-title":"Human Mutation"},{"key":"15028_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/jmedgenet-2013-101937","volume":"51","author":"A Lindstrand","year":"2014","unstructured":"Lindstrand, A. et al. Different mutations in PDE4D associated with developmental disorders with mirror phenotypes. Journal of Medical Genetics \n                           51, 45\u201354 (2014).","journal-title":"Journal of Medical Genetics"},{"key":"15028_CR26","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.cellsig.2014.07.025","volume":"26","author":"T Kaname","year":"2014","unstructured":"Kaname, T. et al. Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis. Cellular Signalling \n                           26, 2446\u20132459 (2014).","journal-title":"Cellular Signalling"},{"key":"15028_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13311-014-0309-7","volume":"12","author":"ME Gurney","year":"2015","unstructured":"Gurney, M. E., D\u2019Amato, E. C. & Burgin, A. B. Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer\u2019s Disease. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics \n                           12, 49\u201356 (2015).","journal-title":"Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics"},{"key":"15028_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.neuron.2010.01.014","volume":"65","author":"N Gervasi","year":"2010","unstructured":"Gervasi, N., Tchenio, P. & Preat, T. PKA dynamics in a Drosophila learning center: coincidence detection by rutabaga adenylyl cyclase and spatial regulation by dunce phosphodiesterase. Neuron \n                           65, 516\u2013529 (2010).","journal-title":"Neuron"},{"key":"15028_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nbt.1598","volume":"28","author":"AB Burgin","year":"2010","unstructured":"Burgin, A. B. et al. Design of Phosphodiesterase Type 4D (PDE4D) Allosteric Modulators for Cognition with Improved Safety. Nature Biotechnology \n                           28, 63\u201370 (2010).","journal-title":"Nature Biotechnology"},{"key":"15028_CR30","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1073\/pnas.94.10.5401","volume":"94","author":"TA Comery","year":"1997","unstructured":"Comery, T. A. et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci USA \n                           94, 5401\u20135404 (1997).","journal-title":"Proc Natl Acad Sci USA"},{"key":"15028_CR31","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1523\/JNEUROSCI.0577-10.2010","volume":"30","author":"A Cruz-Martin","year":"2010","unstructured":"Cruz-Martin, A., Crespo, M. & Portera-Cailliau, C. Delayed stabilization of dendritic spines in fragile X mice. J Neurosci \n                           30, 7793\u20137803 (2010).","journal-title":"J Neurosci"},{"key":"15028_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bbr.2011.04.049","volume":"223","author":"AM Thomas","year":"2011","unstructured":"Thomas, A. M. et al. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome. Behav Brain Res \n                           223, 310\u2013321 (2011).","journal-title":"Behav Brain Res"},{"key":"15028_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0166-4328(01)00401-6","volume":"132","author":"RM Deacon","year":"2002","unstructured":"Deacon, R. M., Croucher, A. & Rawlins, J. N. Hippocampal cytotoxic lesion effects on species-typical behaviours in mice. Behav Brain Res \n                           132, 203\u2013213 (2002).","journal-title":"Behav Brain Res"},{"key":"15028_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuroscience.2012.03.049","volume":"251","author":"CX He","year":"2013","unstructured":"He, C. X. & Portera-Cailliau, C. The trouble with spines in fragile X syndrome: density, maturity and plasticity. Neuroscience \n                           251, 120\u2013128 (2013).","journal-title":"Neuroscience"},{"key":"15028_CR35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/cercor\/10.10.1038","volume":"10","author":"SA Irwin","year":"2000","unstructured":"Irwin, S. A., Galvez, R. & Greenough, W. T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex \n                           10, 1038\u20131044 (2000).","journal-title":"Cereb Cortex"},{"key":"15028_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287::AID-CNE9>3.0.CO;2-R","volume":"407","author":"JA Cherry","year":"1999","unstructured":"Cherry, J. A. & Davis, R. L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. The Journal of Comparative Neurology \n                           407, 287\u2013301 (1999).","journal-title":"The Journal of Comparative Neurology"},{"key":"15028_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/BF00381071","volume":"238","author":"D Bobon","year":"1988","unstructured":"Bobon, D. et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and\/or endogenous depressives. Eur Arch Psychiatry Neurol Sci \n                           238, 2\u20136 (1988).","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"15028_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/00004850-198807000-00006","volume":"3","author":"A Bertolino","year":"1988","unstructured":"Bertolino, A. et al. Rolipram versus imipramine in inpatients with major, \u201cminor\u201d or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol \n                           3, 245\u2013253 (1988).","journal-title":"Int Clin Psychopharmacol"},{"key":"15028_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00004714-198204000-00010","volume":"2","author":"JC Pecknold","year":"1982","unstructured":"Pecknold, J. C., McClure, D. J., Appeltauer, L., Wrzesinski, L. & Allan, T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. Journal of Clinical Psychopharmacology \n                           2, 129\u2013133 (1982).","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"15028_CR40","doi-asserted-by":"publisher","first-page":"152ra127","DOI":"10.1126\/scitranslmed.3004214","volume":"4","author":"EM Berry-Kravis","year":"2012","unstructured":"Berry-Kravis, E. M. et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Science Translational Medicine \n                           4, 152ra127 (2012).","journal-title":"Science Translational Medicine"},{"key":"15028_CR41","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ana.410310105","volume":"31","author":"E Berry-Kravis","year":"1992","unstructured":"Berry-Kravis, E. & Huttenlocher, P. R. Cyclic AMP metabolism in fragile X syndrome. Annals of Neurology \n                           31, 22\u201326 (1992).","journal-title":"Annals of Neurology"},{"key":"15028_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","volume":"72","author":"P Gresele","year":"2011","unstructured":"Gresele, P., Momi, S. & Falcinelli, E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol \n                           72, 634\u2013646 (2011).","journal-title":"Br J Clin Pharmacol"},{"key":"15028_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0898-6568(96)00112-X","volume":"8","author":"M Ito","year":"1996","unstructured":"Ito, M. et al. Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021. Cellular Signalling \n                           8, 575\u2013581 (1996).","journal-title":"Cellular Signalling"},{"key":"15028_CR44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1042\/BJ20050030","volume":"388","author":"W Richter","year":"2005","unstructured":"Richter, W., Jin, S. L. & Conti, M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J \n                           388, 803\u2013811 (2005).","journal-title":"Biochem J"},{"key":"15028_CR45","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cellsig.2013.10.007","volume":"26","author":"MP Kelly","year":"2014","unstructured":"Kelly, M. P. et al. Select 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. Cellular Signalling \n                           26, 383\u2013397 (2014).","journal-title":"Cellular Signalling"},{"key":"15028_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","volume":"74","author":"A Michalon","year":"2012","unstructured":"Michalon, A. et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron \n                           74, 49\u201356 (2012).","journal-title":"Neuron"},{"key":"15028_CR47","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.neuropharm.2005.06.004","volume":"49","author":"QJ Yan","year":"2005","unstructured":"Yan, Q. J., Rammal, M., Tranfaglia, M. & Bauchwitz, R. P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology \n                           49, 1053\u20131066 (2005).","journal-title":"Neuropharmacology"},{"key":"15028_CR48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1124\/jpet.111.183327","volume":"338","author":"LK Pacey","year":"2011","unstructured":"Pacey, L. K., Tharmalingam, S. & Hampson, D. R. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharmacol Exp Ther \n                           338, 897\u2013905 (2011).","journal-title":"J Pharmacol Exp Ther"},{"key":"15028_CR49","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1371\/journal.pone.0000931","volume":"2","author":"DJ Kelley","year":"2007","unstructured":"Kelley, D. J. et al. The cyclic AMP cascade is altered in the fragile X nervous system. PLoS One \n                           2, e931 (2007).","journal-title":"PLoS One"},{"key":"15028_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.brainres.2006.04.032","volume":"1096","author":"D Dlaboga","year":"2006","unstructured":"Dlaboga, D., Hajjhussein, H. & O\u2019Donnell, J. M. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res \n                           1096, 104\u2013112 (2006).","journal-title":"Brain Res"},{"key":"15028_CR51","doi-asserted-by":"crossref","unstructured":"Fujita, M. et al. cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. Molecular Psychiatry (2016).","DOI":"10.1038\/mp.2016.171"},{"key":"15028_CR52","doi-asserted-by":"publisher","first-page":"13445","DOI":"10.1073\/pnas.93.24.13445","volume":"93","author":"CH Bailey","year":"1996","unstructured":"Bailey, C. H., Bartsch, D. & Kandel, E. R. Toward a molecular definition of long-term memory storage. Proc Natl Acad Sci USA \n                           93, 13445\u201313452 (1996).","journal-title":"Proc Natl Acad Sci USA"},{"key":"15028_CR53","doi-asserted-by":"publisher","first-page":"12748","DOI":"10.1523\/JNEUROSCI.3958-09.2009","volume":"29","author":"ER Kandel","year":"2009","unstructured":"Kandel, E. R. The biology of memory: a forty-year perspective. J Neurosci \n                           29, 12748\u201312756 (2009).","journal-title":"J Neurosci"},{"key":"15028_CR54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrd1061","volume":"2","author":"T Tully","year":"2003","unstructured":"Tully, T., Bourtchouladze, R., Scott, R. & Tallman, J. Targeting the CREB pathway for memory enhancers. Nat Rev Drug Discov \n                           2, 267\u2013277 (2003).","journal-title":"Nat Rev Drug Discov"},{"key":"15028_CR55","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1523\/JNEUROSCI.3994-09.2010","volume":"30","author":"JA Brown","year":"2010","unstructured":"Brown, J. A., Gianino, S. M. & Gutmann, D. H. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci \n                           30, 5579\u20135589 (2010).","journal-title":"J Neurosci"},{"key":"15028_CR56","doi-asserted-by":"publisher","first-page":"10518","DOI":"10.1073\/pnas.1834280100","volume":"100","author":"R Bourtchouladze","year":"2003","unstructured":"Bourtchouladze, R. et al. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA \n                           100, 10518\u201310522 (2003).","journal-title":"Proc Natl Acad Sci USA"},{"key":"15028_CR57","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1523\/JNEUROSCI.3735-16.2017","volume":"37","author":"Q Bu","year":"2017","unstructured":"Bu, Q. et al. CREB Signaling Is Involved in Rett Syndrome Pathogenesis. J Neurosci \n                           37, 3671\u20133685 (2017).","journal-title":"J Neurosci"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15028-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15028-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15028-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:14:25Z","timestamp":1671801265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-15028-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15028"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-15028-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]},"assertion":[{"value":"24 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.E.G is an employee of Tetra. Tetra owns BPN14770. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14653"}}